RxDoctor Payments Data

Patrick Thompson, MD

Family Medicine · Aliso Viejo, CANPI 1417938630

Payments from drug & device makers

$7,372in general payments, 2019–2025

Across 116 payments — averaging $63.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Johnson & Johnson$1K
  • Amgen$809
  • Boehringer Ingelheim$722
  • Bayer$243
  • Merck$225
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$50%
  • Food & beverage$7,361100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,372 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,353
Medicare patients
141
Services billed
2,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$50,304
FarxigaDapagliflozin Propanediol26$34,019
XareltoRivaroxaban42$30,160
JanuviaSitagliptin Phosphate30$29,789
JanumetSitagliptin Phos/Metformin Hcl17$15,520
EliquisApixaban13$15,345
Solifenacin Succinate16$3,828
Atorvastatin Calcium259$2,694
Levothyroxine Sodium163$2,264
Fenofibrate57$2,080
Testosterone14$1,534
Losartan Potassium116$1,469
Ondansetron OdtOndansetron12$1,310
Tamsulosin Hcl77$1,203
SynthroidLevothyroxine Sodium12$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$722$50,30437 claims
MerckJanuvia, Janumet$225$45,30847 claims
AstraZenecaFarxiga$2,836$34,01926 claims
Johnson & JohnsonXarelto$1,093$30,16042 claims
PfizerEliquis$166$15,34513 claims
AbbVieSynthroid$67$1,18712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Aliso Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →